- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01841996
Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients
December 15, 2013 updated by: Meiji Seika Pharma Co., Ltd.
A Phase 1 Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study of the Safety, Absorption and Systemic Pharmacokinetics of ME1111 Topical Agent Applied to All Toenails of Adult Moderate to Severe Onychomycosis Patients for 28 Days
This study is Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study.
The purpose is to determine the safety, tolerability, systemic exposure and pharmacokinetics of ME1111 after repeated daily topical application of ME1111 in a maximal use setting in adults with distal subungual onychomycosis of the toenails.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States
-
College Station, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female of any race and between the ages of 18 and 70 inclusive
- Clinically diagnosed onychomycosis of the target nail
- Presence of moderate to severe distal subungual onychomycosis
- A positive potassium hydroxide(KOH) microscopy test result
- A positive fungal culture for a dermatophyte
- Females of childbearing potential must be using a highly effective method of birth control and be willing to remain on the same method of birth control throughout the study
- Good general health as determined by the Investigator based on the subject's medical history and physical examination
Exclusion Criteria:
- Clinical significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize subject's safety
- Subjects with a history of diabetes mellitus
- Unwilling to refrain from the use of nail cosmetics such as clear and/or colored nail solutions
- Females who are nursing, pregnant, or planning a pregnancy during the study
- Failure to complete the specified washout period(s) for the following topical medications: Antifungals drugs within 4 weeks; Anti-inflammatory drugs, corticosteroids, immunomodulators within 2 weeks
- Failure to complete the specified washout period(s) for the following systemic medications: Corticosteroids within 2 weeks; Antifungals for treatment of onychomycosis or any antifungal with known activity against dermatophyte within the previous 24 weeks or 5 half-lives of the drug, whichever is longer; Immunomodulators within 4 weeks
- History of cardiac disease and cardiac arrhythmic activity, or prolonged QT interval
- Received treatment for any type of cancer within the last 6 months
- History of any significant disease or disorder that might put subjects at risk by participating in study or influence results of study
- Nail or anatomic abnormalities of the toe
- Positive test for HIV, Hepatitis B or Hepatitis C
- History of street drug or alcohol abuse
- Donated or lost blood or participated in a clinical study which involved the withdrawal of a large volume of blood (500 mL or more), within the last 6-week
- Participated in any other trial of an investigational drug or device within 30 days or 5 half-lives of the investigational drug or participation in a research study concurrent with this study
- Unable to communicate or cooperate with the Investigator due to comprehension, mental development, or impaired cerebral function
- Presence of any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subjects safety while participating on the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ME1111 solution
|
Once a day for 28 days
|
PLACEBO_COMPARATOR: Vehicle Solution
|
Once a day for 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of adverse events observed throughout the study period.
Time Frame: from Baseline to Day 57
|
from Baseline to Day 57
|
Application site reactions will be evaluated using categorical scales for signs and symptoms throughout the study period.
Time Frame: from Baseline to Day 57
|
from Baseline to Day 57
|
Area under the plasma concentration of ME1111 will be assessed based on the analysis of blood samples over 24 hours
Time Frame: Day 1, 28
|
Day 1, 28
|
Urinary excretion rate will be assessed based on the analysis of urinary samples over 24 hours
Time Frame: Day 1, 28
|
Day 1, 28
|
Plasma trough levels of ME1111
Time Frame: Day 4, 8, 15, 22, 25, 43, 57
|
Day 4, 8, 15, 22, 25, 43, 57
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the nail concentration of ME1111
Time Frame: Day 2, 15, 29, 57
|
Day 2, 15, 29, 57
|
The proportion of subjects who achieve negative KOH microscopy testing results
Time Frame: Day 29, 57
|
Day 29, 57
|
The proportion of subjects who achieve negative fungal culture results
Time Frame: Day 29, 57
|
Day 29, 57
|
The change from baseline in linear toenail growth at Days 29 and 57 will be analyzed
Time Frame: Day 1, 29, 57
|
Day 1, 29, 57
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2013
Primary Completion (ACTUAL)
August 1, 2013
Study Registration Dates
First Submitted
April 18, 2013
First Submitted That Met QC Criteria
April 24, 2013
First Posted (ESTIMATE)
April 29, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
December 17, 2013
Last Update Submitted That Met QC Criteria
December 15, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ME1111-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis
-
Vésale HospitalJanssen-Cilag Ltd.CompletedPrevalence of Onychomycosis | Diabetic Neuropathic Patients | Diagnostic of Onychomycosis | Patients Clinically Suspected of Onychomycosis | Reliability of the Diagnosis of OnychomycosisBelgium
-
DeviceFarm, Inc.Symbio, LLC; Center for Dermatology Clinical Research, Inc.CompletedOnychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton MentagrophytesUnited States
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States
-
Janssen Korea, Ltd., KoreaCompleted
-
ToeFX Inc.Active, not recruiting
-
SATO Pharmaceutical Co., Ltd.Active, not recruitingOnychomycosis of ToenailUnited States
-
Mahidol UniversityCompletedNon-dermatophyte OnychomycosisThailand
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Moberg Pharma ABCompletedDistal Subungual OnychomycosisUnited States, Canada
-
PfizerCompletedOnychomycosis of ToenailsUnited States, Canada
Clinical Trials on ME1111 solution
-
Meiji Seika Pharma Co., Ltd.Completed
-
Coopervision, Inc.CompletedCorneal StainingUnited States
-
Shandong UniversityUnknownImage Quality of Early Esophageal Squamous Neoplasia | Endoscopists'Subjective AssessmentsChina
-
University of NottinghamUnknownPatients Undergoing Open Resection of Colorectal TumoursUnited Kingdom
-
Shandong UniversityCompletedImage Quality | Mucosal IrritationChina
-
University of Texas Southwestern Medical CenterWithdrawnCorneal UlcerUnited States
-
Chiang Mai UniversityCompletedPostoperative Nausea and Vomiting
-
Hospital Clinic of BarcelonaCompletedBronchiectasisSpain
-
Jewish General HospitalWithdrawnPulmonary Arterial HypertensionCanada
-
Aclaris Therapeutics, Inc.Completed